Tenax Therapeutics to Participate in Upcoming Investor Conferences

CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the following investor conferences:

GlobeNewsWire • Nov 25, 2025

Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript

Tenax Therapeutics, Inc. ( TENX ) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF November 13, 2025 4:30 PM EST Company Participants Christopher Giordano - CEO, President & Director Stuart Rich - Chief Medical Officer & Director Sanjiv Shah Barry Borlaug Conference Call Participants David Risinger - Leerink Partners LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Presentation Operator Good afternoon, and welcome to the Tenax Therapeutics Virtual KOL Call.

Seeking Alpha • Nov 14, 2025

Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026

GlobeNewsWire • Nov 12, 2025

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will host a conference call and webcast on Thursday, November 13, 2025, at 4:30 p.m.

GlobeNewsWire • Nov 6, 2025

Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is taking place from November 10-12, 2025, in Boston, MA.

GlobeNewsWire • Nov 3, 2025

Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF

Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF Also Provides Patent Protection for Wide Range of Levosimendan Doses, and its Use in Combination with Various Cardiovascular Drugs in PH-HFpEF CHAPEL HILL, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the European Patent Office (EPO) has notified Tenax of its Intention to Grant a patent that will provide intellectual property (IP) protection for TNX-103 (oral levosimendan), and other formulations of levosimendan, as well as its active metabolites, for use in pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF).

GlobeNewsWire • Sep 16, 2025

Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025

CHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will participate in a fireside chat at the Cantor Global Healthcare Conference 2025, which is taking place from September 3-5, 2025, in New York, NY.

GlobeNewsWire • Aug 28, 2025

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026

GlobeNewsWire • Aug 13, 2025

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026

GlobeNewsWire • May 14, 2025

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts

Tenax Therapeutics is advancing levosimendan in two phase 3 studies for PH-HFpEF, with LEVEL-2 starting in 2025 and topline data from LEVEL expected mid-2026. Levosimendan could be the first disease-modifying therapy for PH-HFpEF, with prior phase 2 success in improving exercise capacity. The company raised $25 million in March 2025, ensuring sufficient funding through 2027 to meet clinical milestones.

Seeking Alpha • Apr 16, 2025